Key result
Low-dose warfarin prophylaxis is recommended for cancer patients with central venous catheters.
Why the study?
Patients with malignancies are at increased risk of venous thromboembolic disease, presenting unique challenges in diagnosis and treatment.
Diagnosis and treatment of VTE in cancer patients should generally parallel that of non-cancer patients, with low-dose warfarin prophylaxis considered in specific scenarios.
May support low-dose warfarin prophylaxis in cancer patients with central catheters; leaves open need for RCTs on idiopathic VTE screening.
Patients with malignancies are at increased risk of developing venous thromboembolic disease. Diagnosis and treatment of deep venous thromboembolism and pulmonary embolism in this group of patients poses some unique challenges, but generally should parallel that of patients without malignancy. Prophylaxis with low-dose warfarin should be considered in patients with indwelling central venous catheters and in some patients receiving chemotherapy for cancer. Although patients who present with idiopathic deep venous thromboembolism or pulmonary embolism may be at increased risk of developing clinically apparent malignancy, there is no data to suggest that an aggressive search for cancer in these patients is more appropriate than routine physical exam and laboratory testing.
No takes yet. Share an insight, caveat, or question.
Sherri S. Durica (1997) conducted a review in Venous thromboembolism in cancer patients. Prophylaxis with low-dose warfarin should be considered in cancer patients with indwelling central venous catheters, while aggressive cancer screening is not recommended for idiopathic VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: